acute myeloid leukemia (AML) | Page 3 | Aplastic Anemia & MDS International Foundation

acute myeloid leukemia (AML)

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1

Author(s): 
Jurjen Versluis, Myriam Labopin, Annalisa Ruggeri, Gerard Socie, Depei Wu, Liisa Volin, Didier Blaise, Noel Milpied, Charles Craddock, Ibrahim Yakoub-Agha, Johan Maertens, Per Ljungman, Anne Huynh, Mauricette Michallet, Eric Deconinck, Patrice Chevallier
Primary Author: 
Jurjen Versluis
Journal Title: 
Blood Advances
Original Publication Date: 
Mar 2017

Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the treatment of choice to consolidate remission in patients with poor-risk

Bone Marrow Diseases: 

AAMDSIF Virtual Film Festival

Over the past few years, several documentaries and dramas about people living with aplastic anemia have been created by independent filmmakers and by patients themselves. These depict the everyday lives of patients coping with a diagnosis, the challenges presented by treatment and the hardship caused by inadequate medical insurance coverage.

Whether fictional movies, or stories about actual patients and families, these portrayals bring you into the world of bone marrow failure disease in an uncompromising and straightforward manner.

Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia

Author(s): 
Natalie Ertz-Archambault, MD; Heidi Kosiorek, MS; Gretchen E. Taylor, MD; et al Katalin Kelemen, MD, PhD; Amylou Dueck, PhD; Janna Castro, BS; Robert Marino, MS; Susanne Gauthier, RN; Laura Finn, MD; Lisa Z. Sproat, MD; Jeanne Palmer, MD; Ruben A. Mesa
Primary Author: 
Natalie Ertz-Archambault, MD
Journal Title: 
JAMA Oncol
Original Publication Date: 
Feb 2017

Importance  Therapy-related myeloid neoplasms are a potentially life-threatening consequence of treatment for autoimmune disease (AID) and an emerging clinical phenomenon.